报价延迟最少15分钟:2026/08/02 05:31 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
316.01 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
4.42/8.31
|
|
企业价值
34.43B
|
| 资产负债 |
|
每股账面净值
45.88
|
| 现金流量 |
|
现金流量率
0.03
|
| 损益表 |
|
收益
5.34B
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers. |
